<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: IPO status board: The good, the bad and the pending</title>
	<atom:link href="http://venturebeat.com/2008/02/21/ipo-status-board-the-good-the-bad-and-the-pending/feed/" rel="self" type="application/rss+xml" />
	<link>http://venturebeat.com/2008/02/21/ipo-status-board-the-good-the-bad-and-the-pending/</link>
	<description>News About Tech, Money and Innovation</description>
	<lastBuildDate>Mon, 23 Nov 2009 13:10:15 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Life-science briefing: Thursday, March 13, 2008 &#187; VentureBeat</title>
		<link>http://venturebeat.com/2008/02/21/ipo-status-board-the-good-the-bad-and-the-pending/comment-page-1/#comment-799268</link>
		<dc:creator>Life-science briefing: Thursday, March 13, 2008 &#187; VentureBeat</dc:creator>
		<pubDate>Tue, 18 Mar 2008 17:04:39 +0000</pubDate>
		<guid isPermaLink="false">http://venturebeat.com/2008/02/21/ipo-status-board-the-good-the-bad-and-the-pending/#comment-799268</guid>
		<description>[...] TissueLink changes name, files for $86M IPO &#8211; The medical-device startup formerly known as TissueLink Medical, now renamed Salient Surgical Technologies, filed to raise $86.3 million in an IPO. That makes Salient either the sixth or seventh life-science company to brave the IPO waters this year &#8212; a number that&#8217;s now maintaining parity with the number of IPOs that have collapsed. [...]</description>
		<content:encoded><![CDATA[<p>[...] TissueLink changes name, files for $86M IPO &#8211; The medical-device startup formerly known as TissueLink Medical, now renamed Salient Surgical Technologies, filed to raise $86.3 million in an IPO. That makes Salient either the sixth or seventh life-science company to brave the IPO waters this year &#8212; a number that&#8217;s now maintaining parity with the number of IPOs that have collapsed. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
